Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older receive two doses of Shingrix, the shingles vaccine, two to six months ...

-- Positive data from 876-patient head-to-head trial versus Shingrix®shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Amezosvatein and Shingrix are adjuvanted recombinant protein subunit vaccines targeting glycoprotein E (gE), the most abundant glycoprotein expressed on the surface of the varicella zoster virus ...